<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38966504</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>06</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2000-9666</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>2</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Journal of community hospital internal medicine perspectives</Title><ISOAbbreviation>J Community Hosp Intern Med Perspect</ISOAbbreviation></Journal><ArticleTitle>Global Perspective on COVID-19 Therapies, Cardiovascular Outcomes, and Implications for Long COVID: A State-of-the-Art Review.</ArticleTitle><Pagination><StartPage>58</StartPage><EndPage>66</EndPage><MedlinePgn>58-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.55729/2000-9666.1308</ELocationID><Abstract><AbstractText>The COVID-19 pandemic has resulted in many therapies, of which many are repurposed and used for other diseases in the last decade such in Influenza and Ebola. We intend to provide a robust foundation for cardiovascular outcomes of the therapies to better understand the rationale for the clinical trials that were conducted during the COVID-19 pandemic, and to gain more clarity on the steps moving forward should the repurposing provide clinical benefit in pandemic situations. With this state-of-the-art review, we aim to improve the understanding of the cardiovascular involvement of the therapies prior to, during, and after the COVID-19 pandemic to provide meaningful findings to the cardiovascular specialists and clinical trials for therapies, moving on from the period of pandemic urgency.</AbstractText><CopyrightInformation>&#xa9; 2024 Greater Baltimore Medical Center.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sarfraz</LastName><ForeName>Azza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Aga Khan University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarfraz</LastName><ForeName>Zouina</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Fatima Jinnah Medical University, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bano</LastName><ForeName>Shehar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fatima Jinnah Medical University, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarfraz</LastName><ForeName>Muzna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>King Edward Medical University, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaan</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rochester General Hospital, Rochester, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minhas</LastName><ForeName>Amna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Fatima Jinnah Medical University, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Razzack</LastName><ForeName>Aminah Abdul</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Larkin Health System, South Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Gaurav</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Larkin Health System, South Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manish</LastName><ForeName>K C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Larkin Health System, South Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makkar</LastName><ForeName>Sarabjot Singh</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Larkin Health System, South Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garimella</LastName><ForeName>Radhika</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Larkin Health System, South Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pandav</LastName><ForeName>Krunal</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Larkin Health System, South Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almonte</LastName><ForeName>Jose</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Larkin Health System, South Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Trissa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Larkin Health System, South Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almonte</LastName><ForeName>Tahlianna</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Larkin Health System, South Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jimenez</LastName><ForeName>Lissandra</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Larkin Health System, South Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pantoga</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Larkin Health System, South Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Mazboudi</LastName><ForeName>Nada</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Larkin Health System, South Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yatzkan</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Larkin Health System, South Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michel</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Larkin Health System, South Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michel</LastName><ForeName>Jack</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Larkin Health System, South Miami, Florida, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Community Hosp Intern Med Perspect</MedlineTA><NlmUniqueID>101601396</NlmUniqueID><ISSNLinking>2000-9666</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cardiovascular</Keyword><Keyword MajorTopicYN="N">Clinical trials</Keyword><Keyword MajorTopicYN="N">Investigational therapies</Keyword><Keyword MajorTopicYN="N">Long covid</Keyword></KeywordList><CoiStatement>Conflicts of interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>5</Day><Hour>4</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38966504</ArticleId><ArticleId IdType="pmc">PMC11221457</ArticleId><ArticleId IdType="doi">10.55729/2000-9666.1308</ArticleId><ArticleId IdType="pii">jchim-14-02-058</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: an overview. J Chinese Med Assoc. 2020 doi: 10.1097/JCMA.0000000000000270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JCMA.0000000000000270</ArticleId><ArticleId IdType="pmc">PMC7153464</ArticleId><ArticleId IdType="pubmed">32134861</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Events as they happen. Rolling updates on coronavirus disease (COVID-19) Who;</Citation></Reference><Reference><Citation>Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA, J Am Med Assoc. 2020;323(13):1239&#x2013;1242. doi: 10.1001/jama.2020.2648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 doi: 10.1016/S2213-2600(20)30079-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30079-5</ArticleId><ArticleId IdType="pmc">PMC7102538</ArticleId><ArticleId IdType="pubmed">32105632</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CI, Postema PG, Arbelo E, et al. SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes. Heart Rhythm. 2020;17(9):1456&#x2013;1462. doi: 10.1016/j.hrthm.2020.03.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2020.03.024</ArticleId><ArticleId IdType="pmc">PMC7156157</ArticleId><ArticleId IdType="pubmed">32244059</ArticleId></ArticleIdList></Reference><Reference><Citation>Roden DM, Harrington RA, Poppas A, Russo AM, Russo AM. Considerations for drug interactions on QTc in exploratory COVID-19 treatment. Circulation. 2020:E906&#x2013;E907. doi: 10.1161/CIRCULATIONAHA.120.047521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.047521</ArticleId><ArticleId IdType="pubmed">32267732</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamp TJ, Hamdan MH, January CT. Chloroquine or hydroxychloroquine for COVID-19: is cardiotoxicity a concern? J Am Heart Assoc. 2020;9(12):e016887&#x2013;e016887. doi: 10.1161/JAHA.120.016887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.120.016887</ArticleId><ArticleId IdType="pmc">PMC7429067</ArticleId><ArticleId IdType="pubmed">32463308</ArticleId></ArticleIdList></Reference><Reference><Citation>Bessi&#xe8;re F, Roccia H, Delini&#xe8;re A, et al. Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit. JAMA Cardiol. 2020 doi: 10.1001/jamacardio.2020.1787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1787</ArticleId><ArticleId IdType="pmc">PMC7195693</ArticleId><ArticleId IdType="pubmed">32936266</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1834</ArticleId><ArticleId IdType="pmc">PMC7195692</ArticleId><ArticleId IdType="pubmed">32936252</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen LS, Dolladille C, Drici MD, et al. Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of the world health organization pharmacovigilance database. Circulation. 2020;142(3):303&#x2013;305. doi: 10.1161/CIRCULATIONAHA.120.048238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.048238</ArticleId><ArticleId IdType="pmc">PMC7365677</ArticleId><ArticleId IdType="pubmed">32442023</ArticleId></ArticleIdList></Reference><Reference><Citation>Christophe B, Nicolas M, Alexis H, Osama AA, Yazine M. Lopinavir-ritonavir treatment for COVID-19 infection in intensive care unit. Circ Arrhythmia Electrophysiol. 2020;13(8):e008798. doi: 10.1161/CIRCEP.120.008798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCEP.120.008798</ArticleId><ArticleId IdType="pmc">PMC7446985</ArticleId><ArticleId IdType="pubmed">32809882</ArticleId></ArticleIdList></Reference><Reference><Citation>Imazio M, Brucato A, Lazaros G, et al. Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality. J Cardiovasc Med (Hagerstown) 2020;21(9):625&#x2013;629. doi: 10.2459/JCM.0000000000001059.</Citation><ArticleIdList><ArticleId IdType="doi">10.2459/JCM.0000000000001059</ArticleId><ArticleId IdType="pubmed">32658005</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragni E, Mangiavini L, Vigan&#xf2; M, et al. Management of osteoarthritis during the COVID-19 pandemic. Clin Pharmacol Ther. 2020;108(4):719&#x2013;729. doi: 10.1002/cpt.1910.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.1910</ArticleId><ArticleId IdType="pmc">PMC7280639</ArticleId><ArticleId IdType="pubmed">32438454</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters MC, Sajuthi S, Deford P, et al. COVID-19-related genes in sputum cells in asthma: relationship to demographic features and corticosteroids. Am J Respir Crit Care Med. 2020;202(1):83&#x2013;90. doi: 10.1164/rccm.202003-0821OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202003-0821OC</ArticleId><ArticleId IdType="pmc">PMC7328313</ArticleId><ArticleId IdType="pubmed">32348692</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyle J, Igbinomwanhia E, Sanchez-Nadales A, Danciu S, Chu C, Shah N. A recovered case of COVID-19 myocarditis and ARDS treated with corticosteroids, tocilizumab, and experimental AT-001. Case Reports. 2020;2(9):1331&#x2013;1336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196388</ArticleId><ArticleId IdType="pubmed">32368755</ArticleId></ArticleIdList></Reference><Reference><Citation>Maskin LP, Olarte GL, Palizas F, et al. High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):743. doi: 10.1186/s13063-020-04646-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-020-04646-y</ArticleId><ArticleId IdType="pmc">PMC7447582</ArticleId><ArticleId IdType="pubmed">32843098</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxwell SR, Moots RJ, Kendall MJ. Corticosteroids: do they damage the cardiovascular system? Postgrad Med. 1994;70(830):863&#x2013;870. doi: 10.1136/pgmj.70.830.863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/pgmj.70.830.863</ArticleId><ArticleId IdType="pmc">PMC2398024</ArticleId><ArticleId IdType="pubmed">7870631</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilbul M, Paparone P, Kim AM, Mutalik S, Ernst CL. Psychopharmacology of COVID-19. Psychosomatics. 2020;61(5):411&#x2013;427. doi: 10.1016/j.psym.2020.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.psym.2020.05.006</ArticleId><ArticleId IdType="pmc">PMC7232075</ArticleId><ArticleId IdType="pubmed">32425246</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Liu Z, Ge J. Scientific research progress of COVID-19/SARS-CoV-2 in the first five months. J Cell Mol Med. 2020;24(12):6558&#x2013;6570. doi: 10.1111/jcmm.15364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.15364</ArticleId><ArticleId IdType="pmc">PMC7264656</ArticleId><ArticleId IdType="pubmed">32320516</ArticleId></ArticleIdList></Reference><Reference><Citation>Aky&#xf5;l FT, Karado&#x11f;an D, G&#xfc;rkan CG, et al. What we learned about COVID-19 so far? Notes from underground. Turkish Thorac J. 2020;21(3):185&#x2013;192. doi: 10.5152/Turk-ThoracJ.2020.20052.</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/Turk-ThoracJ.2020.20052</ArticleId><ArticleId IdType="pmc">PMC7311152</ArticleId><ArticleId IdType="pubmed">32584236</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi N, Abe R, Hattori N, et al. Clinical course of a critically ill patient with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) J Artif Organs. 2020 June;:1&#x2013;4. doi: 10.1007/s10047-020-01183-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10047-020-01183-y</ArticleId><ArticleId IdType="pmc">PMC7298923</ArticleId><ArticleId IdType="pubmed">32556649</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiner &#x17d;, Hatamipour M, Banach M, et al. Statins and the Covid-19 main protease: in silico evidence on direct interaction. Arch Med Sci. 2020;16(2):490&#x2013;496. doi: 10.5114/aoms.2020.94655.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/aoms.2020.94655</ArticleId><ArticleId IdType="pmc">PMC7212226</ArticleId><ArticleId IdType="pubmed">32399094</ArticleId></ArticleIdList></Reference><Reference><Citation>Malvy D, Taburet AM, de Lamballerie X, Mentre F, Extramiana F. The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers. PLoS Neglected Trop Dis. 2020;14(6):1&#x2013;4. doi: 10.1371/journal.pntd.0008259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0008259</ArticleId><ArticleId IdType="pmc">PMC7316222</ArticleId><ArticleId IdType="pubmed">32584817</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Zhang C, Wu Z, Wang G, Zhao H. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: a structured summary of a study protocol for a randomised controlled. Trials. 2020;21(1) doi: 10.1186/s13063-020-04430-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-020-04430-y</ArticleId><ArticleId IdType="pmc">PMC7273382</ArticleId><ArticleId IdType="pubmed">32503657</ArticleId></ArticleIdList></Reference><Reference><Citation>Yener&#xe7;a&#x11f; M, Arslan U, Do&#x11f;du&#x15f; M, et al. Evaluation of electrocardiographic ventricular repolarization variables in patients with newly diagnosed COVID-19. J Electrocardiol. 2020;62:5&#x2013;9. doi: 10.1016/j.jelectrocard.2020.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jelectrocard.2020.07.005</ArticleId><ArticleId IdType="pmc">PMC7373019</ArticleId><ArticleId IdType="pubmed">32731139</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S Food &amp; Drug Administration. Coronavirus (COVID-19) update: FDA issues emergency use authorization for potential COVID-19 treatment.</Citation></Reference><Reference><Citation>Leegwater E, Strik A, Wilms EB, et al. Drug-induced liver injury in a patient with coronavirus disease 2019: potential interaction of remdesivir with P-glycoprotein inhibitors. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa883</ArticleId><ArticleId IdType="pmc">PMC7337726</ArticleId><ArticleId IdType="pubmed">32594120</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulangu S, Dodd LE, Davey RT, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019 doi: 10.1056/NEJMoa1910993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1910993</ArticleId><ArticleId IdType="pmc">PMC10680050</ArticleId><ArticleId IdType="pubmed">31774950</ArticleId></ArticleIdList></Reference><Reference><Citation>EM Agency. Summary on compassionate use. EMA/178637/2020 &#x2013; Rev.2.</Citation></Reference><Reference><Citation>Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 &#x2013; preliminary report. N Engl J Med. 2020 doi: 10.1056/nejmoa2007764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2007764</ArticleId><ArticleId IdType="pubmed">32649078</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebocontrolled, multicentre trial. Lancet. 2020;395(10236):1569&#x2013;1578. doi: 10.1016/S0140-6736(20)31022-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31022-9</ArticleId><ArticleId IdType="pmc">PMC7190303</ArticleId><ArticleId IdType="pubmed">32423584</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 Days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020 August; doi: 10.1001/jama.2020.16349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.16349</ArticleId><ArticleId IdType="pmc">PMC7442954</ArticleId><ArticleId IdType="pubmed">32821939</ArticleId></ArticleIdList></Reference><Reference><Citation>Crump A, Omura S. Ivermectin, &#x201c;Wonder drug&#x201d; from Japan: the human use perspective. Proc Japan Acad Ser B Phys Biol Sci. 2011;87(2):13&#x2013;28. doi: 10.2183/pjab.87.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.2183/pjab.87.13</ArticleId><ArticleId IdType="pmc">PMC3043740</ArticleId><ArticleId IdType="pubmed">21321478</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a specific inhibitor of importin &#x3b1;/&#x3b2;-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J. 2012;443(3):851&#x2013;856. doi: 10.1042/BJ20120150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20120150</ArticleId><ArticleId IdType="pmc">PMC3327999</ArticleId><ArticleId IdType="pubmed">22417684</ArticleId></ArticleIdList></Reference><Reference><Citation>Caly L, Wagstaff KM, Jans DA. Nuclear trafficking of proteins from RNA viruses: potential target for antivirals? Antivir Res. 2012;95(3):202&#x2013;206. doi: 10.1016/j.antiviral.2012.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2012.06.008</ArticleId><ArticleId IdType="pubmed">22750233</ArticleId></ArticleIdList></Reference><Reference><Citation>Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir Res. 2020;178:104787. doi: 10.1016/J.ANTIVIRAL.2020.104787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.ANTIVIRAL.2020.104787</ArticleId><ArticleId IdType="pmc">PMC7129059</ArticleId><ArticleId IdType="pubmed">32251768</ArticleId></ArticleIdList></Reference><Reference><Citation>Saber-Ayad M, Saleh MA, Abu-Gharbieh E. The rationale for potential pharmacotherapy of covid-19. Pharmaceuticals. 2020;13(5) doi: 10.3390/ph13050096.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph13050096</ArticleId><ArticleId IdType="pmc">PMC7281404</ArticleId><ArticleId IdType="pubmed">32423024</ArticleId></ArticleIdList></Reference><Reference><Citation>Awadzi K, Dadzie KY, Shulz-Key H, Haddock DR, Gilles HM, Aziz MA. The chemotherapy of onchocerciasis X. An assessment of four-single dose treatment regimes of MK-933 (Ivermectin) in human onchocerciasis. Ann Trop Med Parasitol. 1985;79(1):63&#x2013;78. doi: 10.1080/00034983.1985.11811889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00034983.1985.11811889</ArticleId><ArticleId IdType="pubmed">3838638</ArticleId></ArticleIdList></Reference><Reference><Citation>Paasch U, Haustein UF. Management of endemic outbreaks of scabies with allethrin, permethrin, and ivermectin. Int J Dermatol. 2000;39(6):463&#x2013;470. doi: 10.1046/j.1365-4362.2000.00990.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-4362.2000.00990.x</ArticleId><ArticleId IdType="pubmed">10944095</ArticleId></ArticleIdList></Reference><Reference><Citation>De Sole G, Remme J, Awadzi K, et al. Adverse reactions after large-scale treatment of onchocerciasis with ivermectin: combined results from eight community trials. Bull World Health Organ. 1989;67(6):707&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2491300</ArticleId><ArticleId IdType="pubmed">2633886</ArticleId></ArticleIdList></Reference><Reference><Citation>Dukuly ZD, Pacque M, Nara A, Taylor HR, Williams PN, Greene BM. A prospective study in high risk subjects of electrocardiographic changes with ivermectin. Trop Med Parasitol. 1990;41(1):73&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">2339252</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon S. FDA letter to stakeholders: do not use ivermectin intended for animals as treatment for COVID-19 in humans.</Citation></Reference><Reference><Citation>Ayogu JI, Odoh AS. Prospects and therapeutic applications of cardiac glycosides in cancer remediation. ACS Comb Sci Published online. 2020 doi: 10.1021/acscombsci.0c00082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscombsci.0c00082</ArticleId><ArticleId IdType="pubmed">32786321</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreenivasan Y, Sarkar A, Manna SK. Oleandrin suppresses activation of nuclear transcription factor-&#x3ba;B and activator protein-1 and potentiates apoptosis induced by ceramide. Biochem Pharmacol. 2003;66(11):2223&#x2013;2239. doi: 10.1016/j.bcp.2003.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2003.07.010</ArticleId><ArticleId IdType="pubmed">14609747</ArticleId></ArticleIdList></Reference><Reference><Citation>Plante KS, Plante JA, Fernandez D, et al. Prophylactic and therapeutic inhibition of in vitro SARS-CoV-2 replication by oleandrin. bioRxiv. 2020 January;15:203489. doi: 10.1101/2020.07.15.203489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.07.15.203489</ArticleId></ArticleIdList></Reference><Reference><Citation>Dey P, Chaudhuri TK. Immunomodulatory activity of Nerium indicum through inhibition of nitric oxide and cyclooxygenase activity and modulation of TH1/TH2 cytokine balance in murine splenic lymphocytes. Cytotechnology. 2016;68(4):749&#x2013;761. doi: 10.1007/s10616-014-9826-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10616-014-9826-9</ArticleId><ArticleId IdType="pmc">PMC4960125</ArticleId><ArticleId IdType="pubmed">25680696</ArticleId></ArticleIdList></Reference><Reference><Citation>Botelho AFM, Miranda ALS, Freitas TG, et al. Comparative cardiotoxicity of low doses of digoxin, ouabain, and oleandrin Cardiovasc toxicol. 2020 doi: 10.1007/s12012-020-09579-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12012-020-09579-1</ArticleId><ArticleId IdType="pubmed">32488807</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;&#xe7;&#xfc;kdurmaz Z, Karapinar H, G&#xfc;l I, Yilmaz A. Complete atrioventricular block after self-ingestion of Nerium oleander for relief of hemorrhoidal complaints. Turk Kardiyol Dernegi Arsivi. 2012;40(2):168&#x2013;170. doi: 10.5543/tkda.2012.01703.</Citation><ArticleIdList><ArticleId IdType="doi">10.5543/tkda.2012.01703</ArticleId><ArticleId IdType="pubmed">22710590</ArticleId></ArticleIdList></Reference><Reference><Citation>Senthilkumaran S, Meenakshisundaram R, Michaels AD, Thirumalaikolundusubramanian P. Electrocardiographic changes during inhalational oleander toxicity. Journal of Electrocardiology. 2011;44:470&#x2013;472. doi: 10.1016/j.jelectrocard.2010.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jelectrocard.2010.12.002</ArticleId><ArticleId IdType="pubmed">21397908</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. Convalescent Plasma COVID-19 letter of authorization.</Citation></Reference><Reference><Citation>Cheng Y, Wong R, Soo YOY, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44&#x2013;46. doi: 10.1007/s10096-004-1271-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-004-1271-9</ArticleId><ArticleId IdType="pmc">PMC7088355</ArticleId><ArticleId IdType="pubmed">15616839</ArticleId></ArticleIdList></Reference><Reference><Citation>Arabi YM, Hajeer AH, Luke T, et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis. 2016;22(9):1554&#x2013;1561. doi: 10.3201/eid2209.151164.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2209.151164</ArticleId><ArticleId IdType="pmc">PMC4994343</ArticleId><ArticleId IdType="pubmed">27532807</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraft CS, Hewlett AL, Koepsell S, et al. The use of TKM-100802 and convalescent plasma in 2 patients with ebola virus disease in the United States. Clin Infect Dis. 2015;61(4):496&#x2013;502. doi: 10.1093/cid/civ334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/civ334</ArticleId><ArticleId IdType="pmc">PMC4542597</ArticleId><ArticleId IdType="pubmed">25904375</ArticleId></ArticleIdList></Reference><Reference><Citation>Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145(8):599&#x2013;609. doi: 10.7326/0003-4819-145-8-200610170-00139.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-145-8-200610170-00139</ArticleId><ArticleId IdType="pubmed">16940336</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosmann F, N&#xf8;rgaard A, Rasmussen MB, Rahbek C, Seeberg J, M&#xf8;ller T. Transfusion-associated circulatory overload in adult, medical emergency patients with perspectives on early warning practice: a single-centre, clinical study. Blood Transfus. 2018;16(2):137&#x2013;144. doi: 10.2450/2017.0228-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.2450/2017.0228-16</ArticleId><ArticleId IdType="pmc">PMC5839610</ArticleId><ArticleId IdType="pubmed">28151385</ArticleId></ArticleIdList></Reference><Reference><Citation>Clifford L, Jia Q, Subramanian A, Yadav H, Schroeder DR, Kor DJ. Risk factors and clinical outcomes associated with perioperative transfusion-associated circulatory overload. Anesthesiology. 2017;126(3):409&#x2013;418. doi: 10.1097/ALN.0000000000001506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0000000000001506</ArticleId><ArticleId IdType="pmc">PMC5309147</ArticleId><ArticleId IdType="pubmed">28072601</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyner MJ, Bruno KA, Klassen SA, et al. Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin Proc. 2020;95(9):1888&#x2013;1897. doi: 10.1016/j.mayocp.2020.06.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2020.06.028</ArticleId><ArticleId IdType="pmc">PMC7368917</ArticleId><ArticleId IdType="pubmed">32861333</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi GP, Sanga V, Barton M. Potential harmful effects of discontinuing ace-inhibitors and arbs in covid-19 patients. Elife. 2020:9. doi: 10.7554/eLife.57278.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.57278</ArticleId><ArticleId IdType="pmc">PMC7198232</ArticleId><ArticleId IdType="pubmed">32250244</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohaim MA, Munir M. A scalable topical vectored vaccine candidate against SARS-CoV-2. Vaccines. 2020;8(3):1&#x2013;16. doi: 10.3390/vaccines8030472.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines8030472</ArticleId><ArticleId IdType="pmc">PMC7565466</ArticleId><ArticleId IdType="pubmed">32846910</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Wang W, Chen Z, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2020 doi: 10.1038/s41586-020-2599-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2599-8</ArticleId><ArticleId IdType="pubmed">32726802</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalita P, Padhi AK, Zhang KYJ, Tripathi T. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2. Microb Pathog. 2020:145. doi: 10.1016/j.micpath.2020.104236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2020.104236</ArticleId><ArticleId IdType="pmc">PMC7196559</ArticleId><ArticleId IdType="pubmed">32376359</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and multiorgan response. Curr Probl Cardiol. 2020;45(8) doi: 10.1016/j.cpcardiol.2020.100618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpcardiol.2020.100618</ArticleId><ArticleId IdType="pmc">PMC7187881</ArticleId><ArticleId IdType="pubmed">32439197</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzo P, Vieceli Dalla Sega F, Fortini F, Marracino L, Rapezzi C, Ferrari R. COVID-19 in the heart and the lungs: could we &#x201c;Notch&#x201d; the inflammatory storm? Basic Res Cardiol. 2020;115(3):31. doi: 10.1007/s00395-020-0791-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00395-020-0791-5</ArticleId><ArticleId IdType="pmc">PMC7144545</ArticleId><ArticleId IdType="pubmed">32274570</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020;81(5):537&#x2013;540. doi: 10.1002/ddr.21656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ddr.21656</ArticleId><ArticleId IdType="pmc">PMC7228359</ArticleId><ArticleId IdType="pubmed">32129518</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L, O&#x2019;Kane AM, Peng H, Bi Y, Motriuk-Smith D, Ren J. SARS-CoV-2 and cardiovascular complications: from molecular mechanisms to pharmaceutical management. Biochem Pharmacol. 2020;178:114114. doi: 10.1016/j.bcp.2020.114114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2020.114114</ArticleId><ArticleId IdType="pmc">PMC7306106</ArticleId><ArticleId IdType="pubmed">32579957</ArticleId></ArticleIdList></Reference><Reference><Citation>McGonagle D, Sharif K, O&#x2019;Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;19(6) doi: 10.1016/j.autrev.2020.102537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102537</ArticleId><ArticleId IdType="pmc">PMC7195002</ArticleId><ArticleId IdType="pubmed">32251717</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannaccone G, Scacciavillani R, Del Buono MG, et al. Weathering the cytokine storm in COVID-19: therapeutic implications. Cardiorenal Med. 2020;10(5):277&#x2013;287. doi: 10.1159/000509483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000509483</ArticleId><ArticleId IdType="pmc">PMC7360507</ArticleId><ArticleId IdType="pubmed">32599589</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley LF, Wohlford GF, Ting C, et al. Role for anti-cytokine therapies in severe coronavirus disease 2019. Crit Care Explor. 2020;2(8):e0178. doi: 10.1097/cce.0000000000000178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/cce.0000000000000178</ArticleId><ArticleId IdType="pmc">PMC7419062</ArticleId><ArticleId IdType="pubmed">32832913</ArticleId></ArticleIdList></Reference><Reference><Citation>Szekely Y, Arbel Y. A review of interleukin-1 in heart disease: where do we stand today? Cardiol Ther. 2018;7(1):25&#x2013;44. doi: 10.1007/s40119-018-0104-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40119-018-0104-3</ArticleId><ArticleId IdType="pmc">PMC5986669</ArticleId><ArticleId IdType="pubmed">29417406</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah SR, Abbasi Z, Fatima M, et al. Canakinumab and cardiovascular outcomes: results of the CANTOS trial. J Community Hosp Intern Med Perspect. 2018;8(1):21&#x2013;22. doi: 10.1080/20009666.2018.1428023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/20009666.2018.1428023</ArticleId><ArticleId IdType="pmc">PMC5804673</ArticleId><ArticleId IdType="pubmed">29441161</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey A, Nikam AN, Shreya AB, et al. Potential therapeutic targets for combating SARS-CoV-2: drug repurposing, clinical trials and recent advancements. Life Sci. 2020:256. doi: 10.1016/j.lfs.2020.117883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117883</ArticleId><ArticleId IdType="pmc">PMC7263255</ArticleId><ArticleId IdType="pubmed">32497632</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SC, Solomon DH, Rogers JR, et al. Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study. Arthritis Rheumatol. 2017;69(6):1154&#x2013;1164. doi: 10.1002/art.40084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40084</ArticleId><ArticleId IdType="pmc">PMC5573926</ArticleId><ArticleId IdType="pubmed">28245350</ArticleId></ArticleIdList></Reference><Reference><Citation>Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75(18):2352&#x2013;2371. doi: 10.1016/j.jacc.2020.03.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.03.031</ArticleId><ArticleId IdType="pmc">PMC7198856</ArticleId><ArticleId IdType="pubmed">32201335</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawashiri SY, Kawakami A, Yamasaki S, et al. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int. 2011;31(4):451&#x2013;456. doi: 10.1007/s00296-009-1303-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-009-1303-y</ArticleId><ArticleId IdType="pubmed">20024554</ArticleId></ArticleIdList></Reference><Reference><Citation>Castagn&#xe9; B, Viprey M, Martin J, Schott AM, Cucherat M, Soubrier M. Cardiovascular safety of tocilizumab: a systematic review and network meta-analysis. PLoS One. 2019;14(8) doi: 10.1371/journal.pone.0220178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0220178</ArticleId><ArticleId IdType="pmc">PMC6675055</ArticleId><ArticleId IdType="pubmed">31369575</ArticleId></ArticleIdList></Reference><Reference><Citation>Haagmans BL, Kuiken T, Martina BE, et al. Pegylated interferon-&#x3b1; protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med. 2004;10(3):290&#x2013;293. doi: 10.1038/nm1001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1001</ArticleId><ArticleId IdType="pmc">PMC7095986</ArticleId><ArticleId IdType="pubmed">14981511</ArticleId></ArticleIdList></Reference><Reference><Citation>Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14(11):1090&#x2013;1095. doi: 10.1016/S1473-3099(14)70920-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(14)70920-X</ArticleId><ArticleId IdType="pmc">PMC7106357</ArticleId><ArticleId IdType="pubmed">25278221</ArticleId></ArticleIdList></Reference><Reference><Citation>Teragawa H, Hondo T, Amano H, Hino F, Ohbayashi M. Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. Jpn Heart J. 1996;37(6):905&#x2013;915. doi: 10.1536/ihj.37.905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1536/ihj.37.905</ArticleId><ArticleId IdType="pubmed">9057685</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-A n update on the status. Mil Med Res. 2020 doi: 10.1186/s40779-020-00240-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40779-020-00240-0</ArticleId><ArticleId IdType="pmc">PMC7068984</ArticleId><ArticleId IdType="pubmed">32169119</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Dosouky II, El Hawari SAM, Emara MH, Hamed EF. Types and predictors of interferon/ribavirin induced cardiac complications in the Egyptian patients with chronic hepatitis C virus. J Indian Coll Cardiol. 2016;6(1):16&#x2013;21. doi: 10.1016/j.jicc.2016.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jicc.2016.01.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Salman H, Bergman M, Bessler H, Alexandrova S, Djaldetti M. The effect of interferon on mouse myocardial capillaries: an ultrastructural study. Cancer. 1999;85(6):1375&#x2013;1379. doi: 10.1002/(SICI)1097-0142(19990315)85:6&lt;1375::AID-CNCR22&gt;3.0.CO;2-D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0142(19990315)85:6&lt;1375::AID-CNCR22&gt;3.0.CO;2-D</ArticleId><ArticleId IdType="pubmed">10189145</ArticleId></ArticleIdList></Reference><Reference><Citation>Parlato S, Santini SM, Lapenta C, et al. Expression of CCR-7, MIP-3&#x3b2;, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood. 2001;98(10):3022&#x2013;3029. doi: 10.1182/blood.V98.10.3022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V98.10.3022</ArticleId><ArticleId IdType="pubmed">11698286</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CC, Chen MY, Lee WS, Chang YL. Potential therapeutic agents against COVID-19: what we know so far. J Chinese Med Assoc. 2020;83(6):534&#x2013;536. doi: 10.1097/JCMA.0000000000000318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JCMA.0000000000000318</ArticleId><ArticleId IdType="pmc">PMC7176266</ArticleId><ArticleId IdType="pubmed">32243270</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalhoub S. Interferon beta-1b for COVID-19. Lancet. 2020;395(10238):1670&#x2013;1671. doi: 10.1016/S0140-6736(20)31101-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31101-6</ArticleId><ArticleId IdType="pmc">PMC7211497</ArticleId><ArticleId IdType="pubmed">32401712</ArticleId></ArticleIdList></Reference><Reference><Citation>Ylldlrlm C, Nieuwenhuis S, Teunissen PF, Horrevoets AJG, Van Royen N, Van Der Pouw Kraan TCTM. Interferon-beta, a decisive factor in angiogenesis and arteriogenesis. J Interferon Cytokine Res. 2015;35(6):411&#x2013;420. doi: 10.1089/jir.2014.0184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2014.0184</ArticleId><ArticleId IdType="pubmed">25714660</ArticleId></ArticleIdList></Reference><Reference><Citation>Goossens P, Gijbels MJJ, Zernecke A, et al. Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. Cell Metabol. 2010;12(2):142&#x2013;153. doi: 10.1016/j.cmet.2010.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2010.06.008</ArticleId><ArticleId IdType="pubmed">20674859</ArticleId></ArticleIdList></Reference><Reference><Citation>Davoudi-Monfared E, Rahmani H, Khalili H, et al. Arandomized clinical trial of the efficacy and safety of interferon &#x3b2;-1a in treatment of severe COVID-19. Antimicrob Agents Chemother. 2020;64(9) doi: 10.1128/AAC.01061-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01061-20</ArticleId><ArticleId IdType="pmc">PMC7449227</ArticleId><ArticleId IdType="pubmed">32661006</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma A, Garcia G, Arumugaswami V, Svendsen C. Human iPSC-derived cardiomyocytes are susceptible to SARS-CoV-2 infection. bioRxiv Prepr Serv Biol. 2020 doi: 10.1101/2020.04.21.051912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.21.051912</ArticleId><ArticleId IdType="pmc">PMC7323681</ArticleId><ArticleId IdType="pubmed">32835305</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon Y, Nukala SB, Srivastava S, et al. Detection of viral RNA fragments in human iPSC-cardiomyocytes following treatment with extracellular vesicles from SARS-CoV-2 coding-sequence-overexpressing lung epithelial cells. bioRxiv Prepr Serv Biol. 2020 doi: 10.1101/2020.05.14.093583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.05.14.093583</ArticleId><ArticleId IdType="pmc">PMC7703503</ArticleId><ArticleId IdType="pubmed">33256833</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Chakravarty T, Chen P, et al. Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series. Basic Res Cardiol. 2020;115(4) doi: 10.1007/s00395-020-0795-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00395-020-0795-1</ArticleId><ArticleId IdType="pmc">PMC7214858</ArticleId><ArticleId IdType="pubmed">32399655</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang JP, Wang X, Moura FA, Siddiqi HK, Morrow DA, Bohula EA. A current review of COVID-19 for the cardiovascular specialist. Am Heart J. 2020;226:29&#x2013;44. doi: 10.1016/j.ahj.2020.04.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2020.04.025</ArticleId><ArticleId IdType="pmc">PMC7252118</ArticleId><ArticleId IdType="pubmed">32497913</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarfraz Z, Sarfraz A, Barrios A, et al. Cardio-pulmonary sequelae in recovered COVID-19 patients: considerations for primary care. J Prim Care Community Health. 2021:12. doi: 10.1177/21501327211023726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/21501327211023726</ArticleId><ArticleId IdType="pmc">PMC8188976</ArticleId><ArticleId IdType="pubmed">34096390</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>